Status:
COMPLETED
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Lead Sponsor:
Ruhr University of Bochum
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting. Unfortunately the variable platelet inhibitory effe...
Detailed Description
Platelet function testing using whole blood aggregometry was performed 48 hours following coronary stenting (either acute coronary syndromes or stable coronary artery disease). The antiplatelet therap...
Eligibility Criteria
Inclusion
- Patients with stable coronary artery disease (CAD) or acute coronary syndromes (ACS) following percutaneous coronary intervention (PCI)
Exclusion
- abnormal platelet count in patients,
- severe liver disorders,
- current gastrointestinal disorders,
- current infections,
- congestive heart failure,
- known bleeding disorders,
- treatment with bivalirudin or glycoprotein IIb/IIIa antagonists within the last 7 days.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01212302
Start Date
October 1 2008
End Date
April 1 2010
Last Update
September 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiovascular Center, Ruhr University Bochum, St. Josef - Hospital, Gudrunstrasse 56
Bochum, North Rhine-Westphalia, Germany, D-44791